Dataset opportunity
Gentronix — 医疗影像数据集机会
Gentronix 持有的中等规模医疗影像数据集，可用于诊断人工智能和计算机视觉。
Score
64.6
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
合作（集团层面）
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
2024年全球医疗影像人工智能市场价值为23.4亿美元，预计复合年增长率为33.48%（来源：SNS Insider）。[4]
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- ✨Signal
专注于预测毒理学和符合 GLP 标准的遗传测试
source ↗
Profile
Dataset profile
Type
医疗影像数据集
Modality
图像
Sector
医疗保健
Volume
中等
Freshness
定期
Rarity
高（专有）
Accessibility
受限
Legal
混合所有权 — 许可权待明确 · 个人身份信息/受监管
Buyer persona
医疗人工智能与诊断影像公司
Gentronix 拥有大量源自其合同研究组织 (CRO) 活动的医学影像数据集，并辅以广泛的医疗记录和监管证据。这种构成使得该数据特别适合训练和验证诊断人工智能算法，因为它不仅包含原始图像，还包含关键的上下文信息和重要的历史对照数据 (HCD)，这对于构建稳健且可批准的模型至关重要。
全球医学影像人工智能市场代表着一个重要的机遇，2024 年市场价值为23.4 亿美元，预计将以惊人的 33.48% 的复合年增长率扩张。[4] 虽然由于 CRO 服务协议、客户保密协议以及 Scantox Group 下的集中决策，访问权限需要协商，但该数据在如此快速增长的市场中的稀有性和质量使其成为任何严肃的人工智能开发者的宝贵战略资产。⚠ 尽职调查（有价值的数据，可协商访问）：数据所有权受 CRO 服务协议管辖；客户保密至关重要；存在重要的历史对照数据 (HCD)，但可能需要匿名化；由 Scantox Group 于 2023 年收购；决策可能在集团层面集中。· 公司：Scantox Group 的子公司。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Gentronix 拥有一个庞大的专有多模态毒理学数据存储库，包括基础的遗传分析显微图像。该数据集对于开发诊断人工智能以预测基因毒性和加速药物安全性筛选的医疗人工智能公司来说是一项稀有资产。在一个年增长率超过 33% 的市场中，这种独特的高稀有度数据通过支持创建高度准确和经过验证的预测模型，提供了显著的竞争优势。
See dimension details ↓- Dataset Specificity90
主导的“医疗记录”，医疗保健行业，3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
定期
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
买家需求异常高，这得益于全球医学影像人工智能市场，预计该市场将以 33.48% 的复合年增长率增长。[4]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
个人身份信息/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
高难度，Scantox Group 的子公司
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 种证据类型，3 次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License36
所有权=混合，许可=权利不明确
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence50
Scantox Group 的子公司
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 个数据需求信号（1 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit83
✓ 良好目标 — 良好目标：Gentronix 是一家合同研究组织 (CRO)，其核心业务是提供毒理学测试服务，从而产生有价值的遗传和分子数据作为副产品。问题：Gentronix 于 2024 年 9 月被 Scantox Group 收购，截至 2026 年 3 月，现以“Scantox Manchester”的品牌在 Scantox 旗下运营。[1]；最初的机会被列为“医学影像数据集”，但该公司实际上专注于基因毒理学，而非医学影像。生成的数据
- Deep Qualification90
⚠ 需要审查 — Gentronix 是一家专注于基因毒理学的合同研究组织 (CRO)，主要生成其客户拥有的临床前数据，这使得假设的“医学影像数据集”既被错误标记，又不太可能可供收购。[数据由公司客户拥有；许可受限；实体不持有该细分市场的特征数据：该公司生成体外或动物模型的临床前毒理学数据，而非来自人类患者的临床数据，如细分市场定义的“诊断影像日志”或“患者结局数据”。[2, 7, 12]；数据集类型与实际活动不符：目标公司的核心业务是基因毒理学，而非一般医学影像。任何影像数据都将是临床前和显微的（例如，数字病理学），而不是标签所暗示的临床诊断影像（X 射线、MRI）。[2, 8, 15]]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
持有者拥有来自核心基因毒理学检测的大量显微图像历史数据库，这对于训练计算机视觉模型以自动检测细胞损伤迹象非常有价值。
Industrial data
这包括来自高通量筛选检测的专有时间序列数据，提供了对基因毒性机制的独特、动态的视图，这对于构建先进的预测安全性模型至关重要。
Regulatory records
该数据集以数十年的符合 GLP 标准的研究数据为基础，提供了用于基准测试和验证药物发现和化学安全性应用人工智能模型的监管级文本和结果。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Gentronix Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market was valued at $2.34 billion in 2024, projected to grow at a 33.48% CAGR (source: SNS Insider). [4]. Investment score 64.6/100 (confidence 0.49). Recommended action: Partnership (group-level).
From the marketplace
Explore live data opportunities
Hartmann International — API 可访问数据集机会
View opportunity →工业Nitsch — 工业传感器数据集机会
View opportunity →医疗保健Dicentra — 可下载数据资产机会
View opportunity →